Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

NCT03794297 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped Inadequate accrual rate

Conditions

Erdheim-Chester Disease

Interventions

DRUG: Dabrafenib Mesylate
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration
DRUG: Trametinib Dimethyl Sulfoxide

Sponsor

National Cancer Institute (NCI)